Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

JAK mutations in high-risk childhood acute lymphoblastic leukemia.

Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, Tasian SK, Loh ML, Su X, Liu W, Devidas M, Atlas SR, Chen IM, Clifford RJ, Gerhard DS, Carroll WL, Reaman GH, Smith M, Downing JR, Hunger SP, Willman CL.

Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8. doi: 10.1073/pnas.0811761106. Epub 2009 May 22.

2.

Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.

Losdyck E, Hornakova T, Springuel L, Degryse S, Gielen O, Cools J, Constantinescu SN, Flex E, Tartaglia M, Renauld JC, Knoops L.

J Biol Chem. 2015 Nov 27;290(48):29022-34. doi: 10.1074/jbc.M115.670224. Epub 2015 Oct 7.

3.

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.

Boer JM, Steeghs EM, Marchante JR, Boeree A, Beaudoin JJ, Beverloo HB, Kuiper RP, Escherich G, van der Velden VH, van der Schoot CE, de Groot-Kruseman HA, Pieters R, den Boer ML.

Oncotarget. 2017 Jan 17;8(3):4618-4628. doi: 10.18632/oncotarget.13492.

4.

Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.

Loh ML, Zhang J, Harvey RC, Roberts K, Payne-Turner D, Kang H, Wu G, Chen X, Becksfort J, Edmonson M, Buetow KH, Carroll WL, Chen IM, Wood B, Borowitz MJ, Devidas M, Gerhard DS, Bowman P, Larsen E, Winick N, Raetz E, Smith M, Downing JR, Willman CL, Mullighan CG, Hunger SP.

Blood. 2013 Jan 17;121(3):485-8. doi: 10.1182/blood-2012-04-422691. Epub 2012 Dec 4.

5.

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.

Harvey RC, Mullighan CG, Chen IM, Wharton W, Mikhail FM, Carroll AJ, Kang H, Liu W, Dobbin KK, Smith MA, Carroll WL, Devidas M, Bowman WP, Camitta BM, Reaman GH, Hunger SP, Downing JR, Willman CL.

Blood. 2010 Jul 1;115(26):5312-21. doi: 10.1182/blood-2009-09-245944. Epub 2010 Feb 4.

6.

Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.

Hornakova T, Staerk J, Royer Y, Flex E, Tartaglia M, Constantinescu SN, Knoops L, Renauld JC.

J Biol Chem. 2009 Mar 13;284(11):6773-81. doi: 10.1074/jbc.M807531200. Epub 2009 Jan 12.

7.

JAK kinases overexpression promotes in vitro cell transformation.

Knoops L, Hornakova T, Royer Y, Constantinescu SN, Renauld JC.

Oncogene. 2008 Mar 6;27(11):1511-9. Epub 2007 Sep 17.

PMID:
17873904
8.

The molecular genetic makeup of acute lymphoblastic leukemia.

Mullighan CG.

Hematology Am Soc Hematol Educ Program. 2012;2012:389-96. doi: 10.1182/asheducation-2012.1.389. Review.

PMID:
23233609
9.

BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.

Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui CH, Relling MV, Shurtleff SA, Downing JR.

Nature. 2008 May 1;453(7191):110-4. doi: 10.1038/nature06866. Epub 2008 Apr 13.

PMID:
18408710
10.

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.

van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, van der Velden VH, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML.

Blood. 2013 Oct 10;122(15):2622-9. doi: 10.1182/blood-2012-10-462358. Epub 2013 Aug 23.

11.

New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.

Mullighan CG.

Clin Cancer Res. 2011 Feb 1;17(3):396-400. doi: 10.1158/1078-0432.CCR-10-1203. Epub 2010 Dec 13.

12.

Beyond Philadelphia: 'Ph-like' B cell precursor acute lymphoblastic leukemias - diagnostic challenges and therapeutic promises.

Izraeli S.

Curr Opin Hematol. 2014 Jul;21(4):289-96. doi: 10.1097/MOH.0000000000000050. Review.

PMID:
24848770
13.

Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.

Yin C, Sandoval C, Baeg GH.

Leuk Lymphoma. 2015 May;56(5):1502-6. doi: 10.3109/10428194.2014.957204. Epub 2015 Jan 21.

PMID:
25146434
14.

Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.

Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, Ariola C, Fodale V, Clappier E, Paoloni F, Martinelli S, Fragale A, Sanchez M, Tavolaro S, Messina M, Cazzaniga G, Camera A, Pizzolo G, Tornesello A, Vignetti M, Battistini A, Cavé H, Gelb BD, Renauld JC, Biondi A, Constantinescu SN, Foà R, Tartaglia M.

J Exp Med. 2008 Apr 14;205(4):751-8. doi: 10.1084/jem.20072182. Epub 2008 Mar 24.

15.

Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia.

Cazzaniga G, van Delft FW, Lo Nigro L, Ford AM, Score J, Iacobucci I, Mirabile E, Taj M, Colman SM, Biondi A, Greaves M.

Blood. 2011 Nov 17;118(20):5559-64. doi: 10.1182/blood-2011-07-366542. Epub 2011 Sep 29.

16.

IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.

Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D, Soverini S, Vitale A, Chiaretti S, Cimino G, Papayannidis C, Paolini S, Elia L, Fazi P, Meloni G, Amadori S, Saglio G, Pane F, Baccarani M, Foà R.

J Clin Oncol. 2009 Nov 1;27(31):5202-7. doi: 10.1200/JCO.2008.21.6408. Epub 2009 Sep 21.

PMID:
19770381
17.

IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia.

Yamashita Y, Shimada A, Yamada T, Yamaji K, Hori T, Tsurusawa M, Watanabe A, Kikuta A, Asami K, Saito AM, Horibe K.

Pediatr Blood Cancer. 2013 Oct;60(10):1587-92. doi: 10.1002/pbc.24571. Epub 2013 Jun 27.

PMID:
23804397
18.

Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.

Lupardus PJ, Ultsch M, Wallweber H, Bir Kohli P, Johnson AR, Eigenbrot C.

Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8025-30. doi: 10.1073/pnas.1401180111. Epub 2014 May 19.

19.

Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.

Vicente C, Schwab C, Broux M, Geerdens E, Degryse S, Demeyer S, Lahortiga I, Elliott A, Chilton L, La Starza R, Mecucci C, Vandenberghe P, Goulden N, Vora A, Moorman AV, Soulier J, Harrison CJ, Clappier E, Cools J.

Haematologica. 2015 Oct;100(10):1301-10. doi: 10.3324/haematol.2015.130179. Epub 2015 Jul 23.

20.

Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.

DeBoer R, Koval G, Mulkey F, Wetzler M, Devine S, Marcucci G, Stone RM, Larson RA, Bloomfield CD, Geyer S, Mullighan CG, Stock W.

Leuk Lymphoma. 2016 Oct;57(10):2298-306. doi: 10.3109/10428194.2016.1144881. Epub 2016 Feb 18.

Supplemental Content

Support Center